Skip to main content
GLP-1 / MetabolicVerified

Cagrilintide

Cagri · NN9838

A long-acting acylated amylin analog engineered to resist aggregation and bind albumin, studied in trials for appetite regulation and weight management, often alongside a GLP-1 agonist. Investigational.

Cagrilintide
Category
GLP-1 / Metabolic
Half-life
~7 days
Common vial
5, 10 mg
Regulatory
Investigational

Tracking and educational reference only, on values you enter or import yourself. Not medical advice or a dosing recommendation.

01

Regulatory status

Investigational

This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.

A regulatory status describes paperwork, not safety. An approved compound can still be wrong for a given person, and an unapproved one is neither thereby dangerous nor thereby fine.

02

Half-life

~7 days (~6-8 days), subcutaneous. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.

03

Storage & handling

Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light.

04

References

  • Kruse et al., J Med Chem 2021
  • Phase 1 PK (once-weekly dosing)

Read the source

Common questions

Cagrilintide, answered plainly.

01What is Cagrilintide?+

A long-acting acylated amylin analog engineered to resist aggregation and bind albumin, studied in trials for appetite regulation and weight management, often alongside a GLP-1 agonist. Investigational. It is also referred to as Cagri, NN9838. It is listed here under GLP-1 / Metabolic as educational reference, which is not a recommendation to use it.

02Is Cagrilintide FDA approved?+

Investigational. This substance is under study in humans, typically under a regulatory authorization such as an Investigational New Drug application. Investigational describes a stage of research and nothing more: it does not mean approval is coming, and it does not indicate that effectiveness has been established.

03What is the half-life of Cagrilintide?+

~7 days (~6-8 days), subcutaneous. A half-life is an educational pharmacology figure describing how long the body takes to clear half of a substance. It is not a schedule and does not imply one.

04How is Cagrilintide stored and handled?+

Supplied lyophilized; store cool, reconstitute before use, then refrigerate and protect from light. Storage conditions come from a manufacturer's own label where one exists, and a compound with no approved label has no agency-reviewed handling instructions at all.

05What vial strengths of Cagrilintide are commonly sold?+

Commonly listed vial strengths are 5, 10 mg. A vial strength is a market fact about how a product is packaged. It is not a dose, and it says nothing about how much of anything belongs in any person.

Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.